Pazopanib (Votrient) The BSG has been informed that pazopanib (Votrient from GSK) for advanced soft tissue sarcoma will not be referred to NICE by the Department of Health. This is understood to be because the numbers of patients are too small to justify the use of the NICE Single Technology Appraisal process, and that the […]

Continue Reading